Synthetic Biologics (NYSEAMERICAN:SYN) Shares Cross Above 50-Day Moving Average of $0.00

Synthetic Biologics, Inc. (NYSEAMERICAN:SYNGet Rating)’s stock price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.00 and traded as high as $1.02. Synthetic Biologics shares last traded at $1.02, with a volume of 57,700 shares trading hands.

Synthetic Biologics Stock Performance

The company has a market cap of $16.16 million, a PE ratio of -0.84 and a beta of 1.38.

Hedge Funds Weigh In On Synthetic Biologics

Hedge funds and other institutional investors have recently modified their holdings of the business. Truist Financial Corp purchased a new position in shares of Synthetic Biologics in the second quarter valued at approximately $256,000. Jane Street Group LLC acquired a new position in shares of Synthetic Biologics in the 1st quarter valued at $80,000. Renaissance Technologies LLC increased its holdings in shares of Synthetic Biologics by 103.9% in the 2nd quarter. Renaissance Technologies LLC now owns 219,000 shares of the company’s stock valued at $47,000 after acquiring an additional 111,600 shares during the period. Northern Trust Corp increased its holdings in shares of Synthetic Biologics by 37.1% in the 1st quarter. Northern Trust Corp now owns 336,399 shares of the company’s stock valued at $96,000 after acquiring an additional 91,000 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of Synthetic Biologics in the 3rd quarter valued at $55,000. 74.38% of the stock is owned by hedge funds and other institutional investors.

Synthetic Biologics Company Profile

(Get Rating)

Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.

See Also

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.